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Abstract
Background: International guidelines recommend coeliac serology in iron deficiency anaemia, and duodenal biopsy for
those tested positive to detect coeliac disease. However, pre-endoscopy serology is often unavailable, thus committing
endoscopists to take routine duodenal biopsies. Some endoscopists consider duodenal biopsy mandatory in anaemia to
exclude other pathologies. We hypothesise that using a point of care test at endoscopy could fill this gap, by providing
rapid results to target anaemic patients who require biopsies, and save costs by biopsy avoidance. We therefore assessed
three key aspects to this hypothesis: 1) the availability of pre-endoscopy serology in anaemia; 2) the sensitivities and cost
effectiveness of pre-endoscopy coeliac screening with Simtomax in anaemia; 3) whether other anaemia-related
pathologies could be missed by this targeted-biopsy approach.
Methods: Group 1: pre-endoscopy serology availability was retrospectively analysed in a multicentre cohort of 934
anaemic patients at 4 UK hospitals. Group 2: the sensitivities of Simtomax, endomysial and tissue-transglutaminase
antibodies were compared in 133 prospectively recruited patients with iron deficiency anaemia attending for a
gastroscopy. The sensitivities were measured against duodenal histology as the reference standard in all patients. The
cost effectiveness of Simtomax was calculated based on the number of biopsies that could have been avoided
compared to an all-biopsy approach. Group 3: the duodenal histology of 153 patients presenting to a separate iron
deficiency anaemia clinic were retrospectively reviewed.
Results: In group 1, serology was available in 361 (33.8 %) patients. In group 2, the sensitivity and negative predictive
value (NPV) were 100 % and 100 % for Simtomax, 96.2 % and 98.9 % for IgA-TTG, and 84.6 % and 96.4 % for EMA
respectively. In group 3, the duodenal histology found no causes for anaemia other than coeliac disease.
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Conclusion: Simtomax had excellent diagnostic accuracy in iron deficiency anaemia and was comparable to
conventional serology. Duodenal biopsy did not identify any causes other than coeliac disease for iron deficiency
anaemia, suggesting that biopsy avoidance in Simtomax negative anaemic patients is unlikely to miss other anaemia-
related pathologies. Due to its 100 % NPV, Simtomax could reduce unnecessary biopsies by 66 % if only those with a
positive Simtomax were biopsied, potentially saving £3690/100 gastroscopies.
Trial registration: The group 2 study was retrospectively registered with clinicaltrials.gov. Trial registration date: 13th
July 2016; Trial registration number: NCT02834429.
Keywords: Coeliac disease, Small intestine, Endoscopy, Histopathology, Iron deficiency anaemia, Diagnostic tests,
Health economics, Screening
Background
The prevalence of coeliac disease is approximately 1 %
[1–5]. However, 75 % of cases remain undiagnosed [6],
possibly due to its insidious onset, and patients do not
always have symptoms. Moreover, the sensitivities of the
endoscopic features of coeliac disease are limited as they
may not always be present or easily recognised [7, 8].
One of the common presenting symptoms is anaemia, af-
fecting 15–26.8 % of untreated patients [9, 10]. It usually
results from malabsorption, leading to iron, folate, and
B12 deficiency [11]. One way to increase the detection of
coeliac disease is by screening individuals with iron defi-
ciency anaemia, which affects 2–5 % of the general popu-
lation in the developed world [12, 13]. At the endoscopy
setting, 2.6–8.7 % of patients presenting with anaemia are
diagnosed with coeliac disease, although the data is sparse
and mainly from small cohorts [10, 14–18]. The current
British Society of Gastroenterology (BSG) iron deficiency
anaemia guidelines recommend routine screening for
coeliac disease with tissue transglutaminase (TTG) and/or
endomysial antibodies (EMA). This is based on the excel-
lent negative predictive value of modern serological tests
for coeliac disease. Individuals who are tested positive
should then undergo a gastroscopy for duodenal biopsy to
confirm the presence of coeliac disease [19]. Anecdotally,
the availability and utilisation of coeliac serology prior to
endoscopy appears to be highly variable, thus committing
clinicians to take duodenal biopsies if serology results are
unavailable. However, this is an expensive way of case de-
tection. A recent Swedish study [10] showed that a routine
duodenal biopsy strategy was ineffective, with a number
needed to biopsy of 577 to detect one case of coeliac
disease, spending more than €30,000 per case. In an
attempt to target patients who require a duodenal biopsy,
Hopper et al. [20] devised a clinical decision tool using a
combination of pre-endoscopy serological testing and
symptom assessment. This algorithm had a 100 %
sensitivity and negative predictive value in detecting
coeliac disease when applied to 2000 prospectively
recruited patients. Yet, the lack of serology availability
prior to endoscopy in real clinical practice seemed to have
precluded the widespread utilisation of this effective and
cost saving clinical decision tool.
One method of filling the gap of unavailable serology
is by using a point of care test at the point of endoscopy.
Several point of care tests are now commercially avail-
able for clinicians and patients to purchase, mostly de-
tecting TTG antibodies. Simtomax, a new point of care
test for coeliac disease, is a finger prick test that provides
rapid results within ten minutes. Simtomax detects coeliac
disease with a unique combination of immunoglobulin A
(IgA) and immunoglobulin G (IgG) antibodies against
deamidated gliadin peptides (DGP) as well as the total
level of IgA [21]. This ensures that results are not affected
by patients with IgA deficiency, which is more common in
people with coeliac disease than the general population
(2.6 % versus 0.14–0.2 %) [22].
In this study, our aim was to evaluate the role of utilising
a pre-endoscopy point of care test for coeliac disease, Sim-
tomax, in iron deficiency anaemia in a cost saving model.
Firstly, we reviewed the rates of adherence to the BSG
guidelines on coeliac serological screening in iron defi-
ciency anaemia in real clinical practice, to demonstrate the
pre-endoscopy availability of serology. We then ascertained
the sensitivities of Simtomax in detecting coeliac disease in
iron deficiency, and established the economic impact of
using Simtomax as a screening tool to target biopsy taking
only in those tested positive for Simtomax. Finally, we ex-
plored whether routine duodenal biopsy would yield any
alternative causes for iron deficiency anaemia other than
coeliac disease, in order to evaluate whether using Simto-
max to target biopsies only in Simtomax positive anaemic
patients would miss other duodenal pathologies causing
anaemia. We chose to review the duodenal histology of pa-
tients from the general population attending a non-coeliac
specialised iron deficiency anaemia clinic at the Northern
General Hospital, because the results would represent real
world data without tertiary referral bias.
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Methods
Study design and participants
Group 1 was a multicentre retrospective analysis of all
patients with anaemia attending a gastroscopy with
duodenal biopsy at four UK hospitals (Addenbrooke’s,
Bradford, Hull and Whipps Cross) over a 12 month
period ranging from 2012 to 2014. The availability of
coeliac serology prior to gastroscopy was reviewed.
Group 2 was a prospective study comparing the sensi-
tivities of Simtomax to conventional serology in an iron
deficient cohort. We prospectively recruited 133 consecu-
tive patients (age range: 18–89 years, median 53) with iron
deficiency with or without anaemia attending a single
coeliac disease research endoscopy list at the tertiary refer-
ral centre Royal Hallamshire Hospital between 2013 and
2015. All recruited patients were consented for the study
prior to the gastroscopy. The patients concurrently under-
took the point of care test, Simtomax, conventional
coeliac serology (IgA-TTG, IgA-EMA) and total IgA levels
at the endoscopy unit. All patients then had a gastroscopy
with quadrantic duodenal biopsy from the second part of
the duodenum and at least one duodenal bulb biopsy.
Patients were excluded from the study if they were known
to have coeliac disease or were on a gluten free diet. Pa-
tients with coagulopathy, active gastrointestinal bleeding
or a suspected carcinoma observed during the examin-
ation were also excluded. Clinical information of the
patients was available to the endoscopist, however the en-
doscopist was blinded to the results of the Simtomax test.
Group 3 was a retrospective histological analysis of
patients attending a separate non-coeliac specific iron
deficiency anaemia clinic at the Northern General Hospital
in 2013–2014. We reviewed their duodenal histology and
hospital case notes to determine the yield of alternative
causes other than coeliac disease in the context of iron
deficiency anaemia.
Point of care test, Simtomax
Simtomax is a point of care test for coeliac disease
manufactured by Augurix Diagnostics, Switzerland. It
detects both IgA and IgG antibodies to DGP, as well as
the total IgA level. The assay is based on lateral flow
immunochromatography using colloidal gold antihuman
antibodies as a signal detector. A sample of 25 μl of ca-
pillary venous blood is required which can be obtained
through a simple finger prick technique. The assay can
also be performed using a plasma sample either in ethyl-
enediaminetetraacetic acid (EDTA) or heparin as well as
a separated serum sample, although a smaller sample vol-
ume of 20 μl is required. The blood sample is then applied
to the test device, followed by the application of 5 drops
of the provided buffer solution. The result can be read
after 10 min. Positive results are indicated by the presence
of a solid red test line for IgA and/or IgG-DGP positivity.
A second single red line indicates the presence of IgA. An
in-built red control line ensures a correctly functioning
test.
Serology
Total IgA was measured on a Behring BN2 nephelometer.
IgA-TTG antibodies were evaluated using enzyme-
linked immunosorbent assay kits (Aesku Diagnostics,
Wendelsheim, Germany). An IgA-TTG titre of > 15
U/ml before 20/5/2014, a new cut off level of >9 U/ml
from 20/5-11/12/2014, and then >7 U/ml from 12/12/
2014 onwards, were regarded as positive as per the manu-
facturer’s guidance. IgA-EMA was detected by immuno-
fluorescence on primate oesophagus sections (Binding
Site, Birmingham, UK).
Biopsies and histology
In total, at least five biopsies were taken from the duode-
num, including at least one from the duodenal bulb, with
each biopsy fixed in formalin at the time of the gastros-
copy. Specimens were then processed, orientated and em-
bedded in paraffin wax by the pathology department.
Standard 3 μm thick sections at three levels were stained
with haematoxylin and eosin, and reported by gastrointes-
tinal histopathologists without knowledge of the Simto-
max results. Villous atrophy was graded according to the
modified Marsh criteria.
Diagnosis of coeliac disease
The presence of villous atrophy (Marsh 3a-3c) on hist-
ology with a positive IgA-EMA or IgA-TTG were required
for the diagnosis of coeliac disease. In cases of seronega-
tive villous atrophy, human leucocyte antigen (HLA)
genotyping was performed, with a negative HLA DQ2 or
DQ8 phenotype used to rule out coeliac disease. Support-
ing information such as family history and response to a
gluten free diet were also taken into account.
Ethics
The study protocol was approved by the Yorkshire and
the Humber Research Ethics committee and registered
with the local research and development department of
Sheffield Teaching Hospital NHS Foundation Trust
under the registration number STH15416. Written con-
sent was obtained from all participants.
Statistical analysis
The sensitivity, specificity, positive (PPV) and negative
predictive values (NPV) of Simtomax, IgA-EMA and
IgA-TTG were measured against duodenal histology as
the reference standard. As the PPV and NPV of a test
are influenced by the pre-test probability, positive (PLR)
and negative likelihood ratios (NLR) were also calculated
as these are less prone to influence by disease prevalence.
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Exact Clopper-Pearson method was used to calculate the
confidence intervals for the diagnostic test sensitivities.
Cost analysis
In the UK, the Health Resource Group tariff (payment
from the National Health Service [NHS] commissioners
to hospitals for providing a service) for a gastroscopy
with duodenal biopsy and a gastroscopy alone are £382
and £344 respectively. This means that £38 would be
saved for the NHS budget if a duodenal biopsy was
avoided for each gastroscopy performed. On the other
hand, there is cross charging between departments for
each service provided. At the Royal Hallamshire
Hospital, the histopathology department charges the
gastroenterology department £86 for the service of ana-
lysing four D2 biopsies and one D1 biopsy (local tariff
may vary among different trusts). We will demonstrate
the financial impact at a local and national level if
Simtomax were to be used to target biopsies in iron
deficient patients with a positive Simtomax test, as
opposed to a routine biopsy strategy.
Results
In group 1, a total of 934 patients with anaemia under-
went a gastroscopy with duodenal biopsy at four UK
hospitals. Coeliac serology was only available in 315
patients (33.8 %) prior to endoscopy. Forty-four (14 %)
serology samples were performed in primary care.
In group 2, 133 patients (88 females) with iron defi-
ciency attending for a gastroscopy at the tertiary referral
centre Royal Hallamshire Hospital were prospectively
recruited. Twenty-six patients (19.5 %) were diagnosed
with coeliac disease. Simtomax correctly identified all
cases of coeliac disease, defined by a combination of a
positive serology (IgA-EMA/IgA-TTG) and Marsh grade
3a-c villous atrophy. The results are shown in Tables 1
and 2. There was one case of a 38 year old Zambian lady
with seronegative villous atrophy secondary to tubercu-
losis. The sensitivity, specificity, PPV and NPV of Simto-
max were 100 %, 82.2 %, 57.8 % and 100 % respectively.
A comparison of the sensitivities of Simtomax, IgA-TTG
and IgA-EMA are shown in Table 3. Please refer to
Fig. 1 for the flow diagram of group 2. There were
no invalid Simtomax results. No adverse events oc-
curred with the Simtomax tests or gastroscopies.
In group 3, 215 patients with iron deficiency anaemia
attended a separate non-coeliac specialised anaemia
clinic at the Northern General Hospital for investigation
from 2013–2014. A total of 175 patients underwent a
gastroscopy, and 153 of those had a duodenal biopsy.
The duodenal histology samples of these 153 patients
were analysed. Two patients had Marsh grade 3 villous
atrophy on histology- one had a positive coeliac serology
and hence was diagnosed with coeliac disease; the other
patient was found to have a colonic tumour during the
course of the IDA investigation and subsequently died.
He never had coeliac serology or HLA genotyping to
confirm the diagnosis. Assuming the latter case to be
coeliac disease, the prevalence of coeliac disease in
group 3 would be 1.3 %. One hundred and forty-one
patients (92.2 %) had normal duodenal histology. Seven
patients (4.6 %) had lymphocytic duodenosis (Marsh
grade 1) on their histology, all of whom had negative
coeliac serology. We reviewed their hospital case notes
and screened for drug causes for lymphocytic duodeno-
sis such as aspirin, proton pump inhibitors, olmesartan,
non steroidal anti-inflammatories and chemotherapy;
autoimmune associations such as type 1 diabetes, thy-
roid disorders etc; and infections such as Helicobacter
pylori, Whipple’s, Giardia etc. Six of these patients had a
cause for or association with lymphocytic duodenosis:
vitiligo, autoimmune hypothyroidism, multiple sclerosis,
aspirin use, proton pump inhibitor use and Helicobacter
pylori infection respectively. We could not find a cause
attributable to the lymphocytic duodenosis in the
remaining one patient, whose helicobacter status was
unknown. Three patients had reactive changes, chronic
duodenitis and submucosal haemangioma respectively
on their duodenal histology which were not the cause
for their iron deficiency anaemia. Please refer to Fig. 2
for the flow chart of group 3 patients.
Cost saving economic model
In our group 2 cohort, 88 out of 133 patients had a
negative Simtomax test. Based on the 100 % sensitivity
and NPV of Simtomax, a duodenal biopsy could have
been avoided in these 88 patients (66.2 %). At the Royal
Hallamshire Hospital, the cost of having duodenal biop-
sies reported (four D2 and one D1 biopsy) is £86, and
the price of each Simtomax test kit is £20. The cost
saving from avoided biopsies in this cohort would be
£7568 (£86x88). After taking into account the cost of
using Simtomax on all patients (£20x133 = £2660), the
overall cost saving in this cohort would be £4908
Table 1 Group 2 patient characteristics and corresponding results
Simtomax positive EMA positive TTG positive Ma0 M1 M2 M3a M3b M3c Coeliac disease
Iron deficiency anaemia (n = 81) 30 13 19 55 7 1 2b 5 10 16 (19.8 %)
Iron deficiency without anaemia (n = 52) 15 10 15 33 8 1 2 2 6 10 (19.2 %)
aMarsh grade
bOne patient had seronegative Marsh grade 3a villous atrophy which was secondary to tuberculosis instead of coeliac disease
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(£7568–£2660) for the gastroenterology department.
This equates to a potential cost saving of £3690 per 100
gastroscopies. At a national level, the difference in the
HRG tariff between a gastroscopy alone and a gastros-
copy with duodenal biopsy paid by the clinical commis-
sioners to the trust is £38. This equates to a cost saving
of £2514/100 gastroscopies for the NHS budget
(£38x88/133x100).
Discussion
Principal findings
We demonstrated with real life data that the availability
of coeliac serology in anaemia prior to gastroscopy was
low (33.8 %). This result is consistent with a study
conducted by Wiland et al. in 2013 demonstrating that
only one third of patients suspected to have coeliac
disease had serology available prior to endoscopy [23].
To our knowledge, this is the first study showing that
a combined IgA/IgG-DGP based point of care test,
Simtomax, had 100 % sensitivity and negative predictive
value in detecting coeliac disease in iron deficient
patients. The positive and negative likelihood ratios were
5.63 and 0 respectively, indicating a negative Simtomax
test effectively rules out coeliac disease in iron deficient
patients. This compares to the results from the study by
Mooney et al. which demonstrated a slightly lower but
still excellent sensitivity of Simtomax at 92.7 % in an
unselected cohort of 508 patients attending for a
gastroscopy [24]. The higher sensitivity of Simtomax in
this study could be due to the specific target population
with iron deficiency anaemia causing a positive ascer-
tainment bias. Although the pre-test probability in group
2 was relatively high, it is similar to that of Mooney et
al.’s study at 13.4 %.
Our group 3 duodenal histology review revealed no
alternative causes for iron deficiency anaemia other than
villous atrophy secondary to coeliac disease. With a
100 % NPV, taking a duodenal biopsy in patients with a
negative Simtomax test would be highly unlikely to yield
any diagnosis for iron deficiency in routine clinical prac-
tice, and hence could be avoided in patients presenting
with iron deficiency with or without anaemia.
The local cost saving of £3690/100 gastroscopies was
based on the coeliac disease prevalence of 19.5 % in our
coeliac enriched group 2 cohort. In a lower prevalence
population, the potential cost saving would be greater. If
we base our calculations on the average coeliac disease
prevalence of 5 % in iron deficient cohorts, [14–18] the
potential cost saving for the gastroenterology department
would be £5826/100 gastroscopies, assuming the same
tariff was applied; and £3456/100 gastroscopies would be
saved at a national level for the NHS budget. This is
excluding a wide range of intangible savings from the
positive knock on effects, such as cost savings from not
using biopsy pots and forceps, staff time and workload for
both the endoscopy and histopathology departments.
Strengths and weaknesses
The strength of our prospective study (group 2) is that
the sensitivities of Simtomax were measured against
duodenal histology rather than serology as the reference
standard. Furthermore, in order to reduce selection bias,
all patients underwent duodenal biopsies irrespective of
their serology or Simtomax results. This sets our study
apart from the three out of four published Simtomax
studies, [25–27] where only patients with a positive
serology or Simtomax test went on to have duodenal
biopsies, which could potentially lead to a positive
ascertainment bias and falsely elevated sensitivities. This
limitation is also common in previous studies on the
sensitivities of coeliac serology. A meta-analysis [28]
published in 2010 on studies comparing IgA-DGP
serology to IgA-TTG serology showed that only two
[29, 30] out of eleven studies were unlikely to have
ascertainment bias, where both of these studies also
biopsied controls.
One of the limitations of our study is the relatively
high pre-test probability in group 2 being investigated at
our tertiary referral centre for coeliac disease, giving a
coeliac disease prevalence of 19.5 %. This referral bias
may falsely increase the positive predictive value of
Simtomax, although the weight of its negative predictive
value may be strengthened.
Another limitation is that even though the non-
specialist group 3 cohort represented real life data from
Table 2 Cross tabulation of Simtomax results by serology and
duodenal histology results
Simtomax
positive
Simtomax
negative
Coeliac disease (positive serology and
Marsh 3 histology)
26 0
No coeliac disease (negative serology
and/or Marsh 0-2 histology)
19 88
Table 3 A comparison of the sensitivities of Simtomax, IgA-TTG and IgA-EMA in group 2
Sensitivity, % (95 % CI) Specificity, % (95 % CI) PPV, % (95 % CI) NPV, % (95 % CI)
Simtomax 100 (86.8–100.0) 82.2 (73.7–89.0) 57.8 (42.2–72.3) 100 (95.9–100.0)
IgA-TTG 96.2 (80.4–99.9) 91.5 (84.5–96.4) 73.5 (55.6–87.1) 99.0 (94.5–100.0)
IgA-EMA 84.6 (65.1–95.6) 99.1 (94.9–100.0) 95.7 (78.1–99.9) 96.4 (91.0–99.0)
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the general population where no other causes for an-
aemia apart from coeliac disease were found on duo-
denal histology, it is a relatively small cohort and may
not be representative of other populations. For instance,
infective causes may be seen in other cohorts, and their
prevalence varies from different populations and
geographical regions. Two Turkish studies reported a
2 % prevalence of Giardia found on duodenal biopsies in
their cohorts with iron deficiency anaemia [31, 32]. On
the other hand, a German study found a 0.2 % preva-
lence of Giardiasis on routine duodenal biopsy in 1000
unselected patients attending for a gastroscopy, [33] and
a study from the U.S. had a 0.3 % yield of Giardiasis on
routine duodenal biopsy in 300 patients presenting with
abdominal pain [34]. Therefore, the cost saving
economic model through biopsy avoidance in iron defi-
cient patients with a negative Simtomax test may not be
applicable to populations where parasitic infections are
common, as infective diagnoses may be missed.
In our group 2 tertiary centre iron deficient cohort,
there was one case of seronegative villous atrophy
secondary to tuberculosis. This is a rare cause of sero-
negative villous atrophy. It must be emphasised that the
group 2 cohort does not reflect what is normally seen in
routine clinical practice, as the Royal Hallamshire Hospital
is a tertiary referral centre. Apart from coeliac disease and
Fig. 1 Flow of participants in group 2 study
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parasitic infections, rarer malabsorptive enteropathies
with villous atrophy have been reported in other studies,
such as in patients with Whipple’s disease, [35] graft ver-
sus host disease, [36] common variable immunodeficiency,
[37, 38] autoimmune enteropathy, [39], and olmesartan
associated enteropathy [40]. The literature has shown that
patients with gastrointestinal parasitic infections and other
rare enteropathies described above typically present with
significant symptoms such as diarrhoea, abdominal pain
and malnutrition, rather than solely with iron deficency
anaemia [34, 37–39]. Therefore, in iron deficient patients
where there is a high index of suspicion for other enterop-
athies, such as malasborptive symptoms or high risk eth-
nicities, the threshold for taking duodenal biopsies should
be lowered.
Our study demonstrated excellent sensitivity and
negative predictive value of Simtomax in iron deficiency,
and its performance was comparable to both IgA-EMA
and IgA-TTG. This is consistent with two other studies
testing Simtomax in high risk groups performed by
Benkebil et al. in 2013 [26] (100 % sensitivity for coeliac
disease in a high risk population) and Bienvenu et al. in
2014 [27] (100 % sensitivity and NPV for coeliac disease
in IgA deficient children, median age 8.4). However,
Bienvenu et al. 2012 [25] showed that the sensitivity of
Simtomax to be slightly lower at 93.1 % when tested on
a paediatric population with clinical suspicion of coeliac
disease, although it should be noted that this sensitivity
was measured against TTG as the reference standard
rather than duodenal histology.
Fig. 2 Flow chart for group 3 cohort analysis
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Conclusion
This is the first study that demonstrated the excellent diag-
nostic accuracy of Simtomax in iron deficiency, which was
comparable to conventional serological testing. With a
100 % sensitivity and negative predictive value, Simtomax
could be used judiciously by clinicians as an effective and
cost saving screening test for coeliac disease in the endo-
scopic setting, by avoiding duodenal biopsies in patients pre-
senting with iron deficiency with a negative Simtomax test.
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